Navigation Links
zPREDICTA Announces Revolutionary Cancer Drug Testing Platform
Date:6/6/2016

zPREDICTA™ today announces the immediate availability of its Reconstructed Bone Marrow (r-Bone™) platform, providing a radical shift in drug testing approach since the 1950s. r-Bone mimics how cells behave in the human body allowing cancer treatments to be tested under the same conditions as would be encountered in a patient. r-Bone helps identify drug candidates for blood cancers, which will ultimately work in patients, and thus, eliminates the guesswork from drug development. r-Bone is already being used in closed pilot programs by customers from 8 major pharmaceutical companies and leading universities, conducting thousands of tests on new anti-cancer drugs.

Methodologies used today to determine which drug candidates will advance to human trials comprise of plastic petri dishes and animals. These models show little predictive value when it comes to identifying the drugs that will demonstrate clinical benefit with over 90% of anticancer drugs failing human trials because they do not work in patients. The r-Bone platform reconstructs human biology where drugs can be tested directly against patients cells, a capability currently lacking in pharmaceutical industry.

"We would like a system that mimics the physiological bone marrow environment so we can work with patient AML bone marrow cells directly," said Hongmin Chen, Principal Scientist at Merck & Co., Inc. who has been working with zPredicta r-Bone kits.

r-Bone is the first product in zPREDICTA’s pipeline covering both blood cancers and solid tumors suitable for use with any drug class, including new immuno-oncology interventions, testing which presents a unique set of challenges not addressed by the available systems. Each product developed by zPREDICTA recreates a specific organ and incorporates specific conditions that arise due to disease. zPREDICTA’s technology provides a comprehensive platform that mimics human biology, which simple enough to be is easily incorporated into the existing drug development workflow. zPREDICTA performs thorough evaluation of each of its product through multiple peer-reviewed studies that validate its technology and demonstrate clinical relevance.

“By more accurately recreating the environment found inside the human body, zPREDICTA’s technology promises to dramatically reduce the time and money required to develop new anti-cancer drugs,” said Paul Buchheit, managing partner at Y Combinator and creator of GMail. “When we decide to invest in a company we look for breakthrough technology and a team that will be able to execute the vision, zPREDICTA has both.”

About zPREDICTA

zPREDICTA, headquartered in San Jose, California is a biotechnology company founded in 2014 by 2 Ph.D. scientists, Julia Kirshner and Mukti Parikh on the principle that cures for human diseases require laboratory systems centered on human biology. zPREDICTA, backed by Y Combinator, the premier Bay Area accelerator, is a pioneer in organ-specific and disease-specific platforms for cancer drug testing. zPREDICTA technology demonstrates high clinical relevance allowing our pharma partners to identify drugs that will be effective in patients, from the hundreds, and often thousands, of compounds in development. The mission of zPREDICTA is to eliminate the guesswork from drug development, and thus, reduce the time and cost of bringing life-saving therapies to market.

Read the full story at http://www.prweb.com/releases/2016/06/prweb13464755.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
2. Annual Conference about Technology Solutions for People with Disabilities Announces Program
3. Probiotic Action Announces Probiotics Lead the Digestive Health Market
4. Verenium Announces Preliminary Financial Results For Fiscal 2012
5. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
6. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
7. EAG Announces New General Manager of Release-To-Production (RTP) Division
8. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
9. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2018)... ... September 06, 2018 , ... ... is releasing the agenda for its upcoming user conference. , This year ... the latest challenges, opportunities, and approaches to regulatory compliance and quality management. , ...
(Date:8/31/2018)... ... , ... Small, wireless and networked describes more than the latest household gadget. ... latest system is tiny in size, but is poised to make a big impact ... implant design is the growing awareness that disease often involves complex interactions between multiple ...
(Date:8/29/2018)... ... August 28, 2018 , ... LabRoots , the leading provider of ... proud to announce the launch of a new gamification feature, allowing users to earn ... one of LabRoots most popular shirts. , Throughout each month, LabRoots users will earn ...
(Date:8/23/2018)... ... August 23, 2018 , ... Visikol began its ... Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer team and Foundation ... path from an idea to a successful biotech company has been a circuitous path ...
Breaking Biology Technology:
(Date:8/31/2018)... ... 30, 2018 , ... In recent years researchers have been ... programs. Longer-target engagement can result in improved efficacy and reduced side effects. Other ... require the alteration of the molecules involved. The limitations of these methods make ...
(Date:8/29/2018)... ... August 28, 2018 , ... ... unlocking the full power of positron emission tomography (PET), today launched its ... Dx is helping clinicians and researchers study and cure debilitating diseases, earlier, ...
(Date:8/23/2018)... ... 2018 , ... Mandy is an eight-year-old mini Australian shepherd and a tripod. When Mandy was ... through three surgeries to try to repair the leg and each time it was unsuccessful. ... her owner, along with her veterinarian, decided to amputate. With only one front leg, ...
Breaking Biology News(10 mins):